Walgreens shoots down motion to investigate concerns over nanoparticles in its infant formula
Walgreens filed a motion with the US Securities and Exchange Commission (SEC) to block an inquiry from shareholders expressing concerns that its store-brand infant formula may contain engineered hydroxyapatite.